April 2, 2021
Mitsubishi Tanabe Pharma said on March 31 that a US federal court has ruled in favor of the company and its partner Janssen Pharmaceuticals in a patent infringement suit over their SGLT2 inhibitor canagliflozin, thereby barring generic entries until July...read more